Skip to main content

Table 2 Analysis of magnesium concentration in monocytes and lymphocytes (in mg/L) and in erythrocytes (in mmol/L)

From: Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study

Parameter

Time point

Study product

Mean (SD)

ANOVA

    

Adj. mean difference

95% CI

p-value

Mg in monocytes and lymphocytes

predose

Biolectra

0.11 (0.034)

0.013

(−0.004, 0.030)

0.1235

Verla

0.12 (0.043)

9 h

Biolectra

0.12 (0.034)

−0.005

(−0.012, 0.002)

0.1614

Verla

0.11 (0.040)

24 h

Biolectra

0.11 (0.029)

−0.007

(−0.018, 0.005)

0.2424

Verla

0.11 (0.023)

Mg in erythrocytes

Predose

Biolectra

2.27 (0.400)

−0.022

(−0.233, 0.189)

0.8294

Verla

2.24 (0.439)

9 h

Biolectra

2.09 (0.287)

−0.001

(−0.116, 0.113)

0.9784

Verla

2.09 (0.269)

24 h

Biolectra

2.10 (0.353)

0.028

(−0.106, 0.162)

0.6655

Verla

2.13 (0.318)

  1. CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla = Magnesium Verla® purKaps. Adjusted mean difference, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean difference does not include 0, respectively if the p-value is <0.05